Drug Trial Radar · NCT06679582
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1
Actual
Start
Dec 4, 2024
Primary completion
Jan 21, 2025
Study completion Jan 21, 2025
Sponsor
- Lead sponsor
- Sutro Biopharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Children's Oncology Group; Innovative Therapies For Children with Cancer Consortium
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML cells.
Conditions
- Acute Myeloid Leukemia (AML)
Interventions
Luveltamab tazevibulinDrug
Luveltamab tazevibulin is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα or FOLR1). It consists of an IgG1 antibody (SP8166) conjugated to cathepsin cleavable 3-aminophenyl hemiasterlin payload, yielding a homogenous ADC with a drug antibody ratio of four. The active warhead (SC209) inhibits tubulin polymerization leading to mitotic arrest and cell death. Other Names: * STRO-002 * Luvelta
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate Efficacy of Luveltamab Tazevibulin MonotherapyTime frame: Up to 12 weeks
Locations
36 sites in 9 countries. Site status is shown where the registry gives one.
Childrens Hospital of Alabama
Birmingham, Alabama
Childrens Hospital of Los Angeles
Los Angeles, California
Lucile Packard Childrens Hospital-Stanford
Palo Alto, California
Children's Hospital of Colorado
Aurora, Colorado
Childrens National Hospital
Washington D.C., District of Columbia
Children's Hospital of Atlanta-Emory
Atlanta, Georgia
Ann & Robert H. Lurie Childrens Hospital
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Minnesota-Masonic Cancer Center
Minneapolis, Minnesota
Children's Mercy Hospital
Kansas City, Missouri
Washington University-School of Medicine
St Louis, Missouri
Columbia University Irving Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
Cook Children's Medical Center
Fort Worth, Texas
Baylor College of Medicine-Dan Duncan Comprehensive Cancer Center
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Massey Cancer Center-Adult Outpatient Pavillion
Richmond, Virginia
Seattle Childrens
Seattle, Washington
St Anna Kinderspital
Vienna, Austria
The Hospital for Sick Children
Toronto, Ontario, Canada
Centre Hospitalier Universitaire-Sainte Justice
Montreal, Quebec, Canada
Rigshopitalet-University of Copenhagen
Copenhagen, Denmark
Institut d'hématologie et d'oncologie pédiatrique
Lyon, France
Hopital Armand Trousseau
Paris, France
Charite-Universitatsmedizin Berlin
Berlin, Germany
Universitatsklinikum-Essen
Essen, Germany
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
Children Hospital Bambino Gesu IRCCS
Rome, Italy
Princess Maxima Center for Pediatric Oncology
CS Utrecht, Netherlands
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Infantil Universitario Nino Jesus-Servicio de Hematologia
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.